No standard treatment for relapsed or refractory anaplastic large-cell lymphoma (ALCL) has been established. This study is a multicenter, open-label trial to examine the effectiveness and safety of transplantation with reduced-intensity conditioning (RIC) for patients under 20 years old with relapsed or refractory ALCL. We defined RIC as the administration of fludarabine (30 mg/mx2/day) for five days plus melphalan (70 mg/mx2/day) for two days and total body irradiation at 4 Gy, followed by allogeneic hematopoietic stem cell transplantation.
|Number of pages||6|
|Journal||Acta medica Okayama|
|Publication status||Published - 2020|
All Science Journal Classification (ASJC) codes
- Biochemistry, Genetics and Molecular Biology(all)